Zynext Ventures

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative therapies using its patented Feldan Shuttle technology. This platform facilitates rapid and secure intracellular delivery of therapeutics, expanding treatment possibilities by accessing previously unreachable cellular components. The company's current pipeline comprises clinical programs leveraging this unique technology to advance novel therapeutic applications.

Illexcor Therapeutics is a biopharmaceutical company focused on developing innovative oral therapies for sickle cell disease. It specializes in creating Hemoglobin S polymerization inhibitors, aiming to provide significant clinical benefits and improve the lives of patients living with this condition.

Neuro42 specializes in the development and commercialization of advanced MRI and robotics technology aimed at improving the diagnosis and treatment of neurological conditions. The company designs portable magnetic resonance imaging machines that facilitate triaging, screening, diagnosing, and intervening in various brain disorders, including traumatic injuries, epilepsy, and tumors. By providing point-of-care solutions, Neuro42 enhances patient access to critical imaging and enables direct robotic interventions outside conventional MRI suites, particularly benefiting individuals who have experienced strokes. This innovative approach aims to streamline neurological care and improve patient outcomes through advanced imaging and intervention technologies.